Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Biosante Pharma Charts. Click Here for more Biosante Pharma Charts.](/p.php?pid=staticchart&s=A%5EBPA&p=8&t=15)
BioSante Pharmaceuticals (AMEX:BPA) today announced that
the Company will participate in the C.E. Unterberg, Towbin Emerging
Growth Life Sciences Conference, being held October 25-26 at The
Palace Hotel in New York City. Stephen M. Simes, president and chief
executive officer of BioSante, will present a corporate overview today
at 3:20 p.m. EDT.
A live audio webcast of the presentation may be accessed via
http://www.wsw.com/webcast/ceut3/bpa/, and a replay will be available
at the same link for 90 days. For more information on C.E. Unterberg,
Towbin and the Emerging Growth Life Sciences Conference, please visit
http://www.unterberg.com.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver bioidentical
estradiol and testosterone. BioSante's lead products include
Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of women
with menopausal symptoms, and LibiGel(TM) (bioidentical testosterone
gel) for the treatment of female sexual dysfunction (FSD). The current
market in the U.S. for estrogen and testosterone products is
approximately $2.5 billion. The transdermal gel formulations used in
the women's gel products are licensed by BioSante from Antares Pharma
Inc. The company also is developing its calcium phosphate
nanotechnology (CaP) for novel vaccines, including biodefense vaccines
for toxins such as anthrax and ricin, and drug delivery systems.
Additional information is available online at: www.biosantepharma.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. The
statements regarding BioSante contained in this press release that are
not historical in nature, particularly those that utilize terminology
such as "may," "will," "should," "likely," "expects," "anticipates,"
"estimates," "believes" or "plans," or comparable terminology, are
forward-looking statements. Forward-looking statements are based on
current expectations and assumptions, and entail various risks and
uncertainties that could cause actual results to differ materially
from those expressed in such forward-looking statements. Important
factors known to BioSante that cause actual results to differ
materially from those expressed in such forward-looking statements are
the difficulty of developing pharmaceutical products, obtaining
regulatory and other approvals and achieving market acceptance, and
other factors identified and discussed from time to time in BioSante's
filings with the Securities and Exchange Commission, including those
factors discussed on pages 19 to 31 of BioSante's Form 10-KSB, which
discussion also is incorporated herein by reference. All
forward-looking statements speak only as of the date of this news
release. BioSante undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.